Published in J Clin Invest on September 01, 1990
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol (1993) 1.52
Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med (1992) 1.33
Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol (1994) 1.32
Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest (1999) 1.29
Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). J Clin Invest (1992) 1.21
Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol (2006) 1.12
Transcription factors nuclear factor I and Sp1 interact with the murine collagen alpha 1 (I) promoter. Mol Cell Biol (1991) 1.12
Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring. Am J Pathol (2003) 1.11
Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol (2010) 1.08
Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. Regulation by transforming growth factor-beta. J Clin Invest (1994) 1.03
Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis (1994) 1.03
A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis (1992) 0.99
Dog mastocytoma cells produce transforming growth factor beta 1. J Clin Invest (1992) 0.97
Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma. Biochem J (1996) 0.97
Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol (2005) 0.96
Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF. Autophagy (2014) 0.95
Retracted Mithramycin selectively inhibits collagen-alpha 1(I) gene expression in human fibroblast. J Clin Invest (1993) 0.91
Interferon-γ promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2. J Cell Physiol (2013) 0.89
Effect of connective tissue growth factor (CCN2/CTGF) on proliferation and differentiation of mouse periodontal ligament-derived cells. Cell Commun Signal (2005) 0.87
Role of cytokines in controlling connective tissue gene expression. Arch Dermatol Res (1994) 0.83
Transforming growth factor beta 2 in epithelial differentiation of developing teeth and odontogenic tumors. J Clin Invest (1993) 0.82
Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol (1997) 0.81
Swimming exercise prevents fibrogenesis in chronic kidney disease by inhibiting the myofibroblast transdifferentiation. PLoS One (2012) 0.80
Enhanced production of transforming growth factor-beta (TGF-beta) during autologous mixed lymphocyte reaction of systemic sclerosis patients. Clin Exp Immunol (1995) 0.77
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. Arthritis Res (2001) 0.76
[Current pathophysiological aspects of systemic sclerosis]. Z Rheumatol (2006) 0.75
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A (1986) 12.14
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem (1986) 10.00
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 6.43
Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol (1987) 5.25
A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-beta. Cell (1988) 3.72
Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J Cell Physiol (1989) 3.58
Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest (1987) 2.74
Purification and fractionation of poly(A)+ RNA. Methods Enzymol (1987) 2.32
Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J (1987) 2.23
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J (1987) 2.23
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest (1989) 2.16
Human epidermal cell cultures: growth and differentiation in the absence of differentiation in the absence of dermal components or medium supplements. Proc Natl Acad Sci U S A (1979) 2.16
Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest (1979) 1.73
Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest (1988) 1.35
Scleroderma and the subcutaneous tissue. Science (1971) 1.32
Transcriptional control of human diploid fibroblast collagen synthesis by gamma-interferon. Biochem Biophys Res Commun (1984) 1.27
Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol (1988) 1.21
Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol (1990) 1.09
Scleroderma. A model for fibrosis. Arch Dermatol (1983) 1.05
Structure of basement membranes in malignant melanoma and nevocytic nevi. J Invest Dermatol (1989) 0.93
Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors. Proc Natl Acad Sci U S A (1982) 0.87
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science (1994) 3.07
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci (1998) 2.60
Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. EMBO J (1991) 2.23
N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization. J Med Chem (1999) 2.13
Integrin alpha 2 beta 1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils. J Cell Biol (1991) 2.08
Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci (2000) 1.92
Biosynthesis of two subunits of type IV procollagen and of other basement membrane proteins by a human tumor cell line. Eur J Biochem (1980) 1.90
Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. J Cell Biol (1995) 1.82
Inhibiting effect of procollagen peptides on collagen biosynthesis in fibroblast cultures. J Biol Chem (1979) 1.80
Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat (2001) 1.68
Inhibition of skin development by overexpression of transforming growth factor beta 1 in the epidermis of transgenic mice. Proc Natl Acad Sci U S A (1993) 1.68
Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. J Invest Dermatol (1981) 1.58
Oncogenic point mutations in exon 20 of the RB1 gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype. Proc Natl Acad Sci U S A (1992) 1.54
(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med (2001) 1.54
Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol (2000) 1.51
Increased deposition of fibulin-2 in solar elastosis and its colocalization with elastic fibres. Br J Dermatol (2001) 1.51
Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol (2001) 1.49
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). Am J Physiol Cell Physiol (2004) 1.49
Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol (1997) 1.49
Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype. J Biol Chem (2001) 1.49
High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys (2001) 1.49
Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci U S A (1997) 1.47
Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer (2002) 1.45
Common structural features of the genes for two stable RNAs from Halobacterium halobium. Nucleic Acids Res (1985) 1.45
Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) (2009) 1.44
Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol (2000) 1.43
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene (2001) 1.41
In situ localization of IgG in epidermolysis bullosa acquisita by immunogold technique. J Am Acad Dermatol (1992) 1.40
Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology (1987) 1.36
Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest (1988) 1.35
Dynamics of basement membrane formation by keratinocyte-fibroblast interactions in organotypic skin culture. Exp Cell Res (1998) 1.33
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) (2008) 1.32
Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum (2004) 1.29
Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med (Berl) (1998) 1.28
Mutations in the hair cortex keratin hHb6 cause the inherited hair disease monilethrix. Nat Genet (1997) 1.25
Regulation of collagen synthesis in fibroblasts within a three-dimensional collagen gel. Exp Cell Res (1988) 1.24
Binding to human jejunum of serum IgA antibody from children with coeliac disease. Lancet (1990) 1.22
Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol (2000) 1.19
Recombinant expression and properties of the human calcium-binding extracellular matrix protein BM-40. Eur J Biochem (1991) 1.19
Mapping of nidogen binding sites for collagen type IV, heparan sulfate proteoglycan, and zinc. J Biol Chem (1993) 1.18
The absence of nidogen 1 does not affect murine basement membrane formation. Mol Cell Biol (2000) 1.17
UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res (1991) 1.17
Type III procollagen is the major collageneous component produced by a continuous rhabdomyosarcoma cell line. FEBS Lett (1979) 1.16
Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum (1990) 1.14
Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem (1999) 1.13
Experiences of patients with false positive results from colorectal cancer screening. Br J Gen Pract (1990) 1.13
Localization of collagen alpha 1(I) gene expression during wound healing by in situ hybridization. J Invest Dermatol (1989) 1.12
Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene (1994) 1.12
Extracellular matrix components synthesized by human amniotic epithelial cells in culture. Cell (1980) 1.12
Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells. Oncogene (1999) 1.11
Disorder of collagen metabolism in a patient with osteogenesis imperfecta (lethal type): increased degree of hydroxylation of lysine in collagen types I and III. Eur J Clin Invest (1981) 1.11
Normal human primary fibroblasts undergo apoptosis in three-dimensional contractile collagen gels. J Invest Dermatol (1998) 1.09
Expanding the keratin mutation database: novel and recurrent mutations and genotype-phenotype correlations in 28 patients with epidermolytic ichthyosis. Br J Dermatol (2011) 1.07
UVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP-1 by interrelated loops of interleukin-1 and interleukin-6. Photochem Photobiol (1994) 1.07
Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol (2000) 1.06
Collagen biosynthesis in systemic scleroderma: regulation of posttranslational modifications and synthesis of procollagen in cultured fibroblasts. J Invest Dermatol (1985) 1.06
Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol (1999) 1.05
Downregulation of collagen synthesis in fibroblasts within three-dimensional collagen lattices involves transcriptional and posttranscriptional mechanisms. FEBS Lett (1993) 1.03
Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol (2005) 1.03
Osteogenesis imperfecta: biochemical and clinical evaluation of 13 cases. Klin Wochenschr (1981) 1.02
The marfan's syndrome. In vitro study of collagen metabolism in tissue specimens of the aorta. Exp Cell Biol (1977) 1.02
Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol (2009) 1.01
Aminoterminal extension peptides from type I procollagen normalize excessive collagen synthesis of scleroderma fibroblasts. Arch Dermatol Res (1978) 1.01
Immunofluorescent localization of type IV collagen and laminin in human skin and its application in junctional zone pathology. Br J Dermatol (1982) 1.01
Caffeine hypersensitivity. Allergy (2002) 1.01
Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. Rheumatology (Oxford) (2009) 1.01
Letters: Fibroblasts from a patient with scleroderma reveal abnormal metabolism. Arch Dermatol Res (1977) 1.01
Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol (1991) 1.00
Synthesis of collagen by human fibroblasts and their SV40 transformants. Exp Cell Res (1980) 1.00
Collagenase gene expression in fibroblasts is regulated by a three-dimensional contact with collagen. FEBS Lett (1989) 1.00
Ultrastructural binding sites of endomysium antibodies from sera of patients with dermatitis herpetiformis and coeliac disease. Gut (1992) 1.00
Type III collagen aminopropeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol (1986) 1.00
Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci (1999) 0.99
Down-regulation of alpha 3(VI) chain expression by gamma-interferon decreases synthesis and deposition of collagen type VI. Eur J Biochem (1989) 0.99
Influence of corticosteroids on chemotactic response and collagen metabolism of human skin fibroblasts. Biochem Pharmacol (1988) 0.98
Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol (2005) 0.98
Inhibition of fibroblast chemotaxis by superoxide dismutase. Eur J Cell Biol (1987) 0.98
The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum (2008) 0.97
Regulation of collagen VI expression in fibroblasts. Effects of cell density, cell-matrix interactions, and chemical transformation. J Biol Chem (1989) 0.97
Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma. Biochem J (1996) 0.97
Changes in calcium and collagen IV binding caused by mutations in the EF hand and other domains of extracellular matrix protein BM-40 (SPARC, osteonectin). J Mol Biol (1994) 0.96
Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun (2001) 0.96
Expression of monocyte chemoattractant protein-1 in the lesional skin of systemic sclerosis. J Dermatol Sci (2001) 0.96
Fibromatosis hyalinica multiplex (juvenile hyalin fibromatosis). Light microscopic, electron microscopic, immunohistochemical, and biochemical findings. Cancer (1985) 0.96
Up-regulation of keratin 17 expression in human HaCaT keratinocytes by interferon-gamma. J Invest Dermatol (1995) 0.96
Mg2+ and Ca2+ differentially regulate beta 1 integrin-mediated adhesion of dermal fibroblasts and keratinocytes to various extracellular matrix proteins. Exp Cell Res (1994) 0.95
Collagen type distribution and macromolecular organization of connective tissue in different layers of human skin. J Invest Dermatol (1984) 0.95
Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments. Coll Relat Res (1983) 0.95
A purine-rich sequence in the human BM-40 gene promoter region is a prerequisite for maximum transcription. Matrix Biol (1995) 0.95
Psoralen photoactivation promotes morphological and functional changes in fibroblasts in vitro reminiscent of cellular senescence. J Cell Sci (1998) 0.94
Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis. Springer Semin Immunopathol (1999) 0.94
The hemidesmosomal plaque. I. Characterization of a major constituent protein as a differentiation marker for certain forms of epithelia. Differentiation (1990) 0.94
Cloning and complete amino acid sequences of human and murine basement membrane protein BM-40 (SPARC, osteonectin). FEBS Lett (1988) 0.94
Inhibition of allergic contact dermatitis to DNCB but not to oxazolone in interleukin-4-deficient mice. J Invest Dermatol (1999) 0.94